Discrepant clinical responses and blood chemokine profiles between two non-steroidal anti-inflammatory medications for children with mild persistent asthma.

Chih-Hsing Hung, Chi-Yuan Li, Yuan-Sheng Lai, Ping-Ching Hsu, Yi-Ming Hua, Kuender D Yang

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2005;16(4):306-9

PMID: 15943593

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

In a randomized study, two oral medications, ketotifen and montelukast, were compared for children with mild persistent asthma. Montelukast revealed faster clinical responses than ketotifen, showing improved exhaled nitric oxide, peak expiratory flow, and asthma scores in 1 wk. After 8-wk of medication, both ketotifen and montelukast revealed improved clinical responses. However, 8 wk of ketotifen, but not montelukast, decreased plasma serum thymus and activation-regulated chemokine (317.854 +/- 207.906 vs. 181.348 +/- 167.109, p < 0.05), macrophage-derived chemokine (355.11 +/- 174.30 vs. 169.19 +/- 62.42, p < 0.05) levels. In conclusion, different oral non-steroidal anti-inflammatory drugs revealed faster or slower treatment responses due to different mechanisms.

Address: Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. [email protected]

DOI: 10.1111/j.1399-3038.2005.00273.x

Link outs

Free resources

Medical:

Subscription / membership required

Full Text Sources:

MeSH Terms: Acetates, Anti-Asthmatic Agents, Asthma, Chemokine CCL17, Chemokine CCL22, Chemokines, Chemokines, CC, Child, Cyclopropanes, Double-Blind Method, Histamine H1 Antagonists, Humans, Ketotifen, Leukotriene Antagonists, Peak Expiratory Flow Rate, Quinolines, Respiratory Function Tests, Sulfides, Th2 Cells